Related Experiment Videos
The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis
J M Grichnik1, J A Burch, J Burchette
1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract:
During development, the interaction of stem cell factor (SCF) with its receptor, KIT, is critical for the survival of melanocytes. Limited in vivo human studies have suggested a possible activating role of SCF on adult human melanocytes. In order to study the impact of this pathway on normal melanocyte homeostasis, human skin xenografts were treated with serial injections of recombinant human SCF or a KIT-inhibitory antibody (K44.2). On histologic evaluation, SCF injection increased, whereas KIT inhibition decreased the number, size, and dendricity of melanocytes. Immunohistochemical expression of melanocyte differentiation antigens, including tyrosinase-related-protein-1 and gp100/pmel17, was markedly increased by treatment with SCF, and decreased by K44.2 treatment. The number of Ki67-positive melanocytes was increased in the SCF-treated tissue, suggesting a direct proliferative effect of SCF; conversely, treatment with K44.2 resulted in melanocyte loss, which did not appear reversible with prolonged treatment. These findings demonstrate that the SCF/KIT pathway remains critical in adult human skin, and that pharmacologic modulation of this single pathway can control cutaneous melanocyte homeostasis.
Insights
The stem cell factor (SCF)/KIT pathway is vital for adult human melanocyte survival and function. Modulating this pathway can control melanocyte numbers and characteristics in skin.
Area of Science:
- Dermatology
- Cell Biology
- Molecular Biology
Background:
- The stem cell factor (SCF) and its receptor KIT play a crucial role in melanocyte development and survival.
- Previous studies suggest SCF may activate adult human melanocytes, but in vivo data is limited.
Purpose of the Study:
- To investigate the impact of the SCF/KIT pathway on normal melanocyte homeostasis in adult human skin.
- To determine if pharmacologic modulation of SCF/KIT signaling can control melanocyte populations.
Main Methods:
- Human skin xenografts were treated with recombinant human SCF or a KIT-inhibitory antibody (K44.2).
- Histologic and immunohistochemical analyses were performed to evaluate melanocyte number, size, dendricity, differentiation markers, and proliferation.
- Ki67 staining was used to assess melanocyte proliferation.
Main Results:
- SCF injection increased melanocyte number, size, and dendricity.
- KIT inhibition (K44.2) decreased melanocyte number, size, and dendricity, leading to melanocyte loss.
- SCF treatment upregulated melanocyte differentiation antigens (tyrosinase-related-protein-1, gp100/pmel17) and increased Ki67-positive melanocytes, indicating proliferation.
- K44.2 treatment decreased differentiation markers and melanocyte proliferation.
Conclusions:
- The SCF/KIT pathway is critical for maintaining melanocyte homeostasis in adult human skin.
- Pharmacologic targeting of the SCF/KIT pathway offers a potential strategy to control cutaneous melanocyte populations.